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Abstract
Background: Glial fibrillary acidic protein (GFAP) is a specific intermediate filament of the cytoskeleton of the astrocyte and
may be used as a specific marker for astrocytic damage. It is detectable in the cerebrospinal fluid following a relapse caused
by Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) spectrum disease. Higher levels are found following an NMO-
related relapse. It is not known if GFAP is also detectable in the serum following such relapses. In particular, it is not known if
lesions limited to the optic nerve release GFAP in sufficient quantities to be detectable within the serum. The aim of this
study was to ascertain the extent to which serum GFAP levels can distinguish between an episode of optic neuritis (ON)
related to NMO spectrum disease and ON from other causes.
Methodology/Principal Findings: Out of 150 patients consecutively presenting to our eye hospital over the period March
2009 until July 2010, we were able to collect a serum sample from 12 patients who had presented with MS-related ON and
from 10 patients who had presented with NMO spectrum disease-related ON. We also identified 8 patients with recurrent
isolated ON and 8 patients with a corticosteroid-dependent optic neuropathy in the absence of any identified aetiology.
GFAP was detectable in the serum of all but three patients (two patients with MS-related ON and one with recurrent optic
neuritis). The median serum GFAP level in the patient group with NMO spectrum disease was 4.63 pg/mL whereas in all
other cases combined together, this was 2.14 pg/mL. The difference was statistically significant (P = 0.01). A similar
statistically significant difference was found when cases with pathology limited to the optic nerve were compared (P = 0.03).
Conclusions: Glial pathology in NMO related optic neuritis is reflected in elevated serum GFAP levels independently of
whether or not there is extra-optic nerve disease.
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Introduction
The conclusions of the optic neuritis treatment trial (ONTT)
have guided the management of isolated idiopathic optic neuritis
(ON) around the world [1]. The ONTT suggested that both no
treatment and intra-venous corticosteroid therapy were equally
satisfactory treatment options in the context of typical ON.
Neuromyelitis Optica (NMO) has emerged as a separate disease
entity even in cases presenting with ON without myelitis, following the
identification of the antibody to Aquaporin 4 [2,3]. There may be a
time lag between the ON episode and the ensuing myelitis [2,4].
Although patients with NMO related ON may present with a more
severe episode of ON than seen in multiple sclerosis (MS), there is little
else to distinguish one type of ON from another at first presentation.
Following theONTT treatment protocol in NMO relatedONpatients
(and offering no treatment) may cause preventable nerve fibre loss [5].
Furthermore, offering subsequent MS immunomodulatory treatments
to NMO patients may be harmful [6].
A small cohort of patients present with acute, isolated ON who
do not have the Aquaporin 4 autoantibody, and who follow a
different course to the majority of cases described in the ONTT.
Some, within this category, require corticosteroids for recovery
and continued immunosuppression for the prevention of further
attacks of ON, whilst others may have repeated attacks of ON
which resolve without treatment. These patients display this
‘atypical’ pattern without showing any evidence of MS on imaging
[7,8]. Some authors have since classified these patients within
syndromic groups such as recurrent isolated optic neuritis
(‘RION’) and chronic relapsing inflammatory optic neuropathy
(‘CRION’) [8,9].
In western Europe, the majority of acute ON cases encountered
resemble the clinical profile described in the ONTT, and hence
require no treatment [10]. However, for those patients with
isolated ON at first presentation who do need immediate
treatment, early identification would be very useful, and may be
sight-saving [5].
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The discovery of the NMO specific autoantibody to the water
channel Aquaporin 4 (found extensively on astrocytic foot
processes) provided evidence for the consideration of NMO as a
separate disease entity from MS.
Recent research has focused on the detection of markers of
astrocytic damage, and their relative expression in NMO and MS.
Glial fibrillary acidic protein (GFAP) is a specific intermediate
filament (IF) of the cytoskeleton of the astrocyte and is absent from
oligodendrocytes and neurons. GFAP measured in cerebrospinal
fluid (CSF) has been shown to be marginally increased in MS
patients when compared with normal controls but substantially
increased in NMO patients undergoing relapses [11–14].
It has until now not been shown if GFAP may be measured in
the serum following an MS or NMO spectrum relapse, especially if
the relapse involves a single lesion in the optic nerve. It is also not
known if ‘atypical’ patterns of ON (such as recurrent or
corticosteroid-dependent: ‘RION’ and ‘CRION’) result in differ-
ing degrees of astrocytic damage.
This is the first study to our knowledge, to investigate levels of
serum GFAP in the context of isolated ON. We asked three main
questions.
1. Is it is possible to detect GFAP in the serum of patients with
ON associated with MS and NMO spectrum disease and is
there a difference in the serum level between these two groups?
It has been shown previously that other biomakers (nitric oxide
and neurofilaments) can be detected in serum following an
episode of optic neuritis even though the volume of diseased
tissue is relatively small and levels are likely to be lower than in
CSF [15].
2. Does isolated optic nerve disease in the absence of lesions
elsewhere result in the release of sufficient levels of GFAP into
the serum, to be detectable?
3. Do the levels of serum GFAP (and hence the degree of
astrocytic damage) found in patients with ‘atypical’ presenta-
tions of ON, such as ‘CRION’ and ‘RION’ pattern ON,
resemble MS or NMO, or are they distinct from both? A
significant difference between ‘CRION’ and MS patients
would allow the former to be identified earlier and given urgent
immunotherapy.
We also investigate if the level of serum GFAP is related to the
degree of recovery from the most recent attack of ON. We show
that it is possible to measure GFAP in the serum of optic nerve
patients and that this measurement may allow us to identify NMO
from non-NMO related ON.
Methods
Objectives
1. To investigate if NMO Spectrum ON can be distinguished
from MS associated ON by measuring serum GFAP following an
episode of ON, even in the absence of extra-optic nerve lesions.
2. To investigate if serum GFAP levels in patients with ‘atypical’
patterns of ON (such as ‘CRION’ or ‘RION’ pattern ON)
resemble those found in patients with NMO spectrum ON.
Participants
Out of 150 patients consecutively presenting to our eye hospital
over the period March 2009 until July 2010 with an episode of
acute ON at Moorfields Eye Hospital or The National Hospital of
Neurology and Neurosurgery, Queen Square, we were able to
collect a serum sample (within 210 days of onset of the ON
episode) from 12 patients who had presented with MS related ON
and from 10 patients who had presented with NMO spectrum
disease-related ON. MS was diagnosed based on the McDonald
criteria [16]. The NMO spectrum group were all positive for the
Aquaporin 4 antibody, 6 patients presented with isolated ON only
and 4 patients also had myelitis at some point in the past or
concurrently and hence satisfied Wingerchuk’s criteria for
diagnosis [17]. We also identified 8 patients who had suffered
from ON which relapsed upon the withdrawal of steroid therapy,
in whom MR imaging the optic nerve, brain and spinal cord did
not show demyelination (ie, any lesion in addition to the optic
neuropathy), and there had been at least 3 relapses in the absence
of any other evidence for disease including sarcoidosis, based on
imaging and serology. We labeled this group as ‘CRION’ [9]. In a
fourth group, 8 patients had experienced at least two episodes of
ON. 5 of these patients were treated with a short course of steroid
therapy at their own request, and did not relapse upon its
withdrawal. The patients displayed no evidence of demyelination
elsewhere. As they displayed a recurrent pattern of ON in the
absence of evidence of other pathology, we labeled this group as
‘RION’ [8]. All patients except for those with MS related ON
were tested for the Aquaporin 4 antibody. All patients with other
existing neurological/connective tissue/ vasculitic/ ophthalmic
disease were excluded from the study.
The demographic data of the participants are given in Table 1.
Patient Groups
MS group. The MS group was made up of 12 patients. In 4
of these, the ON episode was the first episode of MS which was
diagnosed subsequently. Four of the 8 patients in whom the
Table 1. The age, gender and ethnic background of patients across all categories are shown.
ON Subtype1
MS related ON NMO spectrum ‘CRION’ pattern ON ‘RION’ pattern ON
White Caucasian ethnic background 6 2 3 6
Not ‘white Caucasian’ ethnic background 6 8 7 2
F:M 8:3 7:3 9:1 5:3
Median Age in years (s.d.)2 32 (11) 34 (10) 44 (10) 42 (13)
A higher female: male ratio is observed in all groups. The majority of patients with NMO spectrum and ‘CRION’ pattern ON do not have a ‘white Caucasian’ ethnic
background.
1ON=optic neuritis, NMO=Neuromyelitis Optica, MS =Multiple Sclerosis, ‘CRION’ = ‘chronic relapsing inflammatory optic neuropathy’, ‘RION’ = Recurrent Isolated Optic
Neuritis.
2s.d. = standard deviation.
doi:10.1371/journal.pone.0023489.t001
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diagnosis was already confirmed at the point of sample collection
had experienced previous non-optic nerve relapses. None of the
participants were on long term immunomodulatory therapy.
NMO spectrum group. This group was formed of 10 patients.
All patients were seropositive for the antibody to Aquaporin 4. Of
these, 6 patients had suffered from ON only, without any evidence of
myelitis; these patients will be referred to as ‘AQP4+ON’. The
remaining 4 patients satisfied Wingerchuk’s criteria [17].
‘RION’ group. This group consisted of 8 patients. Two of the
patients presented with their first attack during the time of the
study. None of the participants were on long term treatment of any
kind.
‘CRION’ group. This group included 8 patients, all of whom
had been diagnosed prior to the current episode of ON, and all of
whom were on some form of immunosuppression at the time of
the attack.
Serum Analysis for GFAP level
Serum samples were collected in polypropylene tubes centri-
fuged (2,000 g for 10 minutes) and stored immediately at 280uC
in 1.5–2 mL Eppendorf tubes (polypropylene) until analysis.
Serum GFAP was measured in duplicates with the analyst being
blinded to all other information using an in-house developed
ELISA [18]. The analytical accuracy of the assay was found to be
5.8% (interassay coefficient of variation).
Aquaporin 4
All patients were tested for Serum aquaporin 4 antibodies
(AQP4) aside from those with a diagnosis of MS associated ON.
Testing was carried out at the Wetherall Institute of Molecular
Medicine, University of Oxford by a method using the
fluorescence immunoprecipitation assay (FIPA) technique de-
scribed elsewhere [19].
Measurement of visual recovery
All patients were clinically assessed using a Snellen chart. We
defined visual recovery in terms of the number of lines of
improvement using a Snellen chart, from the point of the worst
visual acuity during the acute episode to the visual acuity
measured at a follow up assessment after recovery. In the case of
bilateral optic neuritis, we used the reading from the eye with the
greater degree of recovery. For comparison of the visual acuity
during the peak of visual loss during an episode of ON, we
converted the Snellen reading to a LogMar measurement for ease
of comparison of visual acuities across the groups.
Ethics
Informed written consent was obtained from all patients. The
Central London Research Ethics Committee granted ethical
permission for the study (REC reference number: 09/H0716/63).
The study was conducted in accordance with the principles
expressed in the Declaration of Helsinki.
Statistical methods
SigmaPlot and SigmaStat statistical software were used to
perform statistical analysis on the data. Tukey Box Plots were used
to graphically represent the data showing either the 5th, 25th, 50th,
75th and 95th percentiles, or the 25th, 50th, and 75th percentiles.
The student t-test was used for the comparison of two samples if
the samples followed a normal distribution. Where this was not the
case, the Mann–Whitney Rank Sum test was used instead. The
Kruskal-Wallis One Way Analysis of Variance was used to
compare multiple groups. Multinear regression analysis was used
to assess the influence of more than one independent factors on a
dependent factor. A p-value of 0.05 was accepted as significant.
Results
The serum GFAP levels in pg/mL measured in patients with
NMO spectrum disease, MS-related ON, and ‘CRION’ and
‘RION’ syndromes are represented in Figure 1. Both the mean
and median values of serum GFAP demonstrate a trend in the
following order: NMO.‘CRION’.‘RION’.MS.
The serum GFAP level was measured after variable time
intervals (until 210 days) following the acute optic neuritis episode
onset. Figure 2 demonstrates the time interval (in days) after which
the serum GFAP was measured in all patient groups, and the
serum GFAP level.
1) Serum GFAP levels in NMO vs MS and in NMO vs all
AQP4 negative cases
A comparison of the NMO Spectrum group with the MS group
is made in Table 2. The Mann-Whitney Rank Sum Test
confirmed a statistically significant difference (P= 0.02) between
the median value of the NMO spectrum group (4.63 pg/mL) and
the median value of the MS group (1.96 pg/mL). 75% of readings
within the NMO spectrum group fell above 3.3 pg/mL whereas
75% of readings within the MS group fell below 2.94 pg/mL and
the 99% confidence interval of the NMO spectrum group was
4.36 pg/mL, whereas that of the MS group was 2.56 pg/mL.The
MS group showed an excess kurtosis of 7.0 compared to 1.3 in the
NMO group.
The NMO Spectrum group is compared with all other patients
(MS, ‘RION’ syndrome and ‘CRION’ syndrome combined
together) in Table 2. The Mann-Whitney Rank Sum Test
confirmed a statistically significant difference (P= 0.01) between
the median value of the NMO spectrum group (4.63 pg/mL) and
the median value of the three other groups combined together
(2.14 pg/mL). 75% of readings within the NMO spectrum group
fell above 3.30 pg/mL whereas 75% of readings within the three
other groups, when combined, fell below 3.77 pg/mL.
The Mann-Whitney Rank Sum Test did not show a statistically
significant difference between the median values of the MS and
‘CRION’ groups (P= 0.44), nor between the median values of the
NMO and ‘CRION’ groups (P= 0.17).
Serum GFAP is statistically significantly higher in NMO
spectrum patients than in patients with MS, as well as all
Aquaporin 4 antibody negative patients combined together.
2) Serum GFAP levels in AQP4 positive patients with
isolated optic neuritis vs. all AQP4 negative cases
The question arises as to whether it is the occurrence of extra-
optic nerve disease – such as myelitis – that is the factor
determining the higher GFAP levels in NMO.
The serum GFAP levels (in pg/mL) measured in patients
without extra-optic nerve disease (AQP4+ON, ‘CRION’ syn-
drome and ‘RION’ syndrome) are shown in Figure 3. The
descriptive statistics for the comparison of AQP4+ON patients
with all antibody negative patients who do not have extra-optic
nerve disease (‘RION’ syndrome and ‘CRION’ syndrome) are
shown in Table 3. Use of the t-test confirmed a statistically
significant difference (P = 0.03) between the mean value of the
AQP4+ON group (6.46 pg/mL) and the mean value of the
‘RION’ and ‘CRION’ syndrome groups combined (2.94 pg/mL).
The 99% confidence interval of the AQP4+ON group was
7.70 pg/mL whereas those of the ‘RION’ and ‘CRION’ groups
were 2.82 pg/mL and 2.83 pg/mL respectively.
Serum GFAP Levels in NMO Spectrum Optic Neuritis
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Serum GFAP is statistically significantly higher in Aquaporin 4
antibody positive patients without extra-optic nerve disease than in
all Aquaporin 4 antibody negative patients combined together.
3) Serum GFAP levels and visual outcome
This analysis was carried out with 9 NMO spectrum patients, 9
MS patients and 7 ‘RION’ patients on whom we had accurate
data on visual acuity. The worst visual acuity during the most
recent episode of acute ON (baseline visual acuity, measured as a
LogMar conversion of the Snellen reading) was not significantly
different between the groups. A Kruskal-Wallis Analysis showed
there was no statistically significant difference between the groups
(P= 0.30) and the Mann-Whitney Rank Sum Test confirmed the
absence of a statistically significant difference between the median
baseline visual acuity of the NMO spectrum group (1.0) and that
of the MS and ‘RION’ syndrome groups (0.8), when combined.
The Mann-Whitney Rank Sum Test also confirmed the absence of
a statistically significant difference between the median baseline
visual acuity of the NMO spectrum group (1.0) and that of the MS
group (0.8).
Multiple linear regression analysis did not demonstrate a
correlation between the number of lines (on a Snellen chart) of
recovery following optic neuritis and the serum GFAP level
measured, taking into account the number of days following the
optic neuritis episode, when the serum measurement was under-
taken.
Discussion
This study has shown that Glial pathology in NMO related
optic neuritis is reflected in elevated serum GFAP levels
independently of whether or not there is extra-optic nerve disease.
Figure 2. Time in Days Following the Onset of Acute Optic
Neuritis, When Serum GFAP Measurements Were Acquired,
Versus the Serum GFAP Level in pg/mL. Although many patients’
serum was tested within 50 days of onset, their serum samples were
collected up to 210 days following the onset of acute optic neuritis.
doi:10.1371/journal.pone.0023489.g002
Figure 1. Serum GFAP Level (pg/mL) Across All Groups, Shown in Tukey Box Plot. Tukey box plot showing the median, 25th percentile and
75th percentile of serum GFAP level measurements in each group. The 5th and 95th percentile of groups 1 and 2 are also shown.
doi:10.1371/journal.pone.0023489.g001
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The level of serum GFAP during an attack of ON has no
prognostic value.
Our results suggest it may be possible to separate patients with
NMO spectrum disease from those with MS when they present
with an episode of acute ON, on the basis of their group means. A
larger number of cases would be required in order to determine
the sensitivity and specificity of the test in individual cases, as the
difference in serum GFAP levels was not great enough to prevent
some overlap in values across the groups. The significant
difference in the level of serum GFAP found in this study
nonetheless holds promise for the use of serum GFAP to predict
whether a previously healthy patient presenting for the first time is
likely to require a non-ONTT based treatment protocol.
The differences in the level of serum GFAP between patients in
the groups we have studied were less dramatic than those reported
in a recent study examining levels of GFAP in the cerebrospinal
fluid of patients with NMO and MS, where the overall levels of
cerebrospinal fluid GFAP measured during a relapse were
reported to be 2 476.668,815.0 ng/mL in NMO and 0.86
0.4 ng/mL in MS [12]. However, a relapse in the form of optic
neuritis was found to result in markedly lower levels of
cerebrospinal GFAP (median 6.1; range 1.1–56.1) than myelitis
(median 593.9; range 1.2–47,843.3 ng/mL).
All our patients experienced a relapse in the form of optic
neuritis. Additionally, measurement of GFAP in the serum instead
Table 2. Descriptive statistics of serum GFAP measurements (pg/mL) in patients across all categories3 are shown.
NMO (pg/mL)
MS related ON
(pg/mL) ‘RION’ (pg/mL) CRION’ (pg/mL)
All patients with non-
NMO spectrum ON
Mean 5.90 2.60 2.71 3.16 2.79
Std Dev1 4.25 2.85 2.28 2.29 2.46
C.I. of Mean2 3.04 1.81 1.91 1.91 0.96
Median 4.63 1.96 2.58 2.56 2.14
25% 3.30 1.33 0.80 1.46 1.11
75% 7.21 2.94 4.16 4.39 3.77
Skewness 1.29 2.42 0.62 1.08 1.60
Kurtosis 1.30 6.99 20.45 1.12 3.16
99% C.I.2 4.36 2.56 2.82 2.83
The fifth column shows the merged data of all ‘non-NMO spectrum’ patients. Both mean and median values for the serum GFAP level were highest in the NMO
spectrum category and lowest in the MS related ON category. The results from patients with ‘atypical’ patterns of optic neuritis (‘RION’ and ‘CRION’ pattern) fell halfway
between the two groups. Patients in the NMO spectrum group showed the highest variance. All values are stated to within 2 decimal places.
1Std Dev = standard deviation.
2C.I. = Confidence Interval.
3ON= optic neuritis, AQP4+ON=Aquaporin 4 autoantibody positive ON, ‘CRION’ = ‘chronic relapsing inflammatory optic neuropathy’, ‘RION’ = Recurrent Isolated Optic
Neuritis.
doi:10.1371/journal.pone.0023489.t002
Figure 3. Serum GFAP Level (pg/mL) Measurements in Patients
without Extra-Optic Nerve Disease (AQP4+ON, ‘RION’ and
‘CRION’ Groups). Tukey box plot showing the median, 25th
percentile and 75th percentile of serum GFAP level measurements in
each group.
doi:10.1371/journal.pone.0023489.g003
Table 3. Descriptive statistics of serum GFAP measurements
(pg/mL) in patients without optic nerve disease1 are shown.
NMO
(pg/mL)
‘RION’
(pg/mL)
‘CRION’
(pg/mL)
R+C
(pg/mL)
Mean 6.46 2.71 3.16 2.94
Std Dev1 4.68 2.28 2.29 2.22
C.I. of Mean2 4.91 1.91 1.91 1.18
Median 5.76 2.58 2.56 2.58
25% 3.30 0.80 1.46 0.95
75% 7.21 4.16 4.39 4.39
Skewness 1.45 0.62 1.08 0.75
Kurtosis 2.72 20.45 1.12 20.09
99% C.I.3 7.70 2.82 2.83
AQP4+ON patients showed the highest levels of serum GFAP as well as the
highest variance. Both the median and mean values for serum GFAP level are
higher in AQP4+ON patients compared to the values in the NMO spectrum
group as a whole (4.63 pg/mL, 5.90 pg/mL). All values are stated to within 2
decimal places.
1Std Dev = standard deviation.
2C.I. = Confidence Interval.
3ON=optic neuritis, AQP4+ON=Aquaporin 4 autoantibody positive ON,
‘CRION’ = ‘chronic relapsing inflammatory optic neuropathy’, ‘RION’ = Recurrent
Isolated Optic Neuritis.
doi:10.1371/journal.pone.0023489.t003
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of the cerebrospinal fluid is likely to result in a lower measurement
following passage across the blood-brain-barrier and may explain
the difference in the levels reported between the two studies.
Takano et al (2010) carried out cerebrospinal fluid measurements
in almost half of all patients within a week of onset and all patients
within 25 days of onset and demonstrated a sharp decline in GFAP
level (a factor of 100 within 25 days) over this time. In contrast,
serum analysis in our study was carried out in fewer than half of all
patients within 14 days and in all patients up to 210 days following
onset. This may be an additional reason behind the difference in
GFAP levels detected in the two studies.
We did not have sufficient numbers of patients to make a
comparison between patients presenting for the first time with
what is later diagnosed as NMO spectrum disease, versus patients
presenting for the first time with what later becomes MSON.
The observation that isolated astrocytic damage in the optic
nerves is sufficient to release GFAP at concentrations quantifiable
from the serum, and that these are highest in NMO spectrum ON
further supports a role for serum GFAP in the diagnosis of NMO
spectrum ON at first presentation.
The absence of a statistically significant difference between the
serum GFAP values in the ‘CRION’ pattern ON group and either
the MS or NMO spectrum groups may be due to the small sample
size, or may be a consequence of immunosuppression. Most
patients with ‘CRION’ were immunosuppressed prior to the most
recent episode of ON and this immunosuppression may have
protected against the full extent of inflammation occurring during
the attack, and limited astrocytic damage.
As our testing methods for the autoantibody to Aquaporin 4
have been shown to be 76% sensitive and 100% specific, there
exists a possibility that the ‘RION’ and ‘CRION’ cohorts within
this study also contain NMO spectrum patients which may have
reduced the differences in serum GFAP levels between the groups
[19]. A previous study has described cases of ‘RION’ pattern ON
developing into NMO spectrum disease over time [2]. Our study
provides some evidence that the astrocytic damage occurring
within the ‘RION’ pattern of ON is less extensive than that
occurring in AQP4+ON, and that patients with a ‘RION’ pattern
of ON may instead have a similar extent of astrocytic damage to
MS associated ON. Although all patients labeled as having a
‘RION’ pattern of ON in our study showed no demyelination on
imaging, the overlap between a ‘RION’ pattern of optic neuritis
and MS has been described [20].
Patients from the AQP4+ON, MSON and ‘RION’ groups
suffered from statistically similar degrees of visual loss during the
acute episode of ON (P= 0.30). In all three groups, no correlation
of the level of visual recovery following the episode was found with
the serum GFAP level. Although this may be the result of testing
small sample sizes and the wide temporal window within which
sampling was carried out (210 days), an additional reason may be
that visual outcome reflects neuronal loss, not astrocytic damage.
Serum GFAP may be released as a result of astrocytic damage
without resulting neuronal loss, for which other neuron-specific
markers such as neurofilaments have been shown to be better
biomarkers [15].
We were unable to measure the level of serum GFAP over time
within individual patients and this is a significant limitation of our
study. The rate of decay of serum GFAP level following astrocyte
damage is not known.
Serum GFAP levels need to be measured in patients presenting
with acute isolated ON for the first time, with no known medical
history, in order to accurately determine the role of GFAP in the
diagnosis of optic neuritis.
The number of participants was small and a larger cohort would
be required to reach further conclusions. This would require a
longer time period of observation in a long-term prospective study.
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